Peritoneal Adhesion Clinical Trial
Official title:
Chinese PLA Generation Hospital
Background: Malignant peritoneal adhesion is a common complication and prognostic factor of
ovarian cancer and other primary abdominal tumors. The incidence of peritoneal adhesion in
advanced primary peritoneal tumor is 32-56%, which has increased by more than 10 times in
the recent decade. Malignant peritoneal adhesion is closely associated with the morbidity
and mortality of malignant intestinal obstruction. The peritoneal adhesion may aggravates
the abdominal symptoms and reduce quality of life. Further, the peritoneal adhesion may
impede treatment of primary tumor, such as operation or chemotherapy, lead to a poor
prognosis.
Objective: This study aims to treat malignant peritoneal adhesion with the combination of
antiangiogenic agent and chemotherapy, evaluate the efficacy and safety of intraperitoneal
antiangiogenic agent plus chemotherapy. As explosive endpoints, we will examination the
expression of VEGF-A in peritoneal cavity during the treatment.
n/a